In partnership with Horizon Discovery, TD2 now offers high-throughput in vitro and in vivo screening with Horizon's panel of more than 200 genetically-defined human isogenic cell-lines, which are designed to accurately mirror cancer patient genetics.

You can now access a fully integrated drug discovery service that will accelerate the isolation and optimization of targeted therapeutic agents. These engineered lines and their matched controls can be rapidly deployed in target validation, drug screening, patient selection for increased clinical activity, drug resistance and drug re-profiling.

> Click here to learn more

A model of collaborative synergy "Our diversity of expertise provides opportunities for new ideas and better products to be thoroughly explored."

> Click here for more

  — Dr. Stephen Gately, President, TD2